#BEGIN_DRUGCARD DB00548

# AHFS_Codes:
Not Available

# ATC_Codes:
D10AX03

# Absorption:
Approximately 4% of the topically applied azelaic acid is systemically absorbed.

# Biotransformation:
Mainly excreted unchanged in the urine but undergoes some b-oxidation to shorter chain dicarboxylic acids.

# Brand_Mixtures:
Not Available

# Brand_Names:
Azelex
Emerox 1110
Emerox 1144
Emery's L-110
Finacea
Finevin
Skinoren

# CAS_Registry_Number:
123-99-9

# ChEBI_ID:
48131

# Chemical_Formula:
C9H16O4

# Chemical_IUPAC_Name:
nonanedioic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Azelaic acid is a saturated dicarboxylic acid found naturally in wheat, rye, and barley. It is a natural substance that is produced by Malassezia furfur (also known as Pityrosporum ovale), a yeast that lives on normal skin. It is effective against a number of skin conditions, such as mild to moderate acne, when applied topically in a cream formulation of 20%. It works in part by stopping the growth of skin bacteria that cause acne, and by keeping skin pores clear. Azelaic acid's antimicrobial action may be attributable to inhibition of microbial cellular protein synthesis.

# Dosage_Forms:
Cream	Topical

# Drug_Category:
Antineoplastic Agents
Dermatologic Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.57

# Experimental_Logs:
-1.89

# Experimental_Water_Solubility:
2400 mg/L (at 20 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Azelaic Acid

# HET_ID:
AZ1

# Half_Life:
The observed half-lives in healthy subjects are approximately 45 minutes after oral dosing and 12 hours after topical dosing, indicating percutaneous absorption rate-limited kinetics.

# InChI_Identifier:
InChI=1S/C9H16O4/c10-8(11)6-4-2-1-3-5-7-9(12)13/h1-7H2,(H,10,11)(H,12,13)

# InChI_Key:
InChIKey=BDJRBEYXGGNYIS-UHFFFAOYSA-N

# Indication:
For the topical treatment of mild-to-moderate inflammatory acne vulgaris.

# KEGG_Compound_ID:
C08261

# KEGG_Drug_ID:
D03034

# LIMS_Drug_ID:
548

# Mechanism_Of_Action:
The exact mechanism of action of azelaic acid is not known. It is thought that azelaic acid manifests its antibacterial effects by inhibiting the synthesis of cellular protein in anaerobic and aerobic bacteria, especially <i>Staphylococcus epidermidis</i> and <i>Propionibacterium acnes</i>. In aerobic bacteria, azelaic acid reversibly inhibits several oxidoreductive enzymes including tyrosinase, mitochondrial enzymes of the respiratory chain, thioredoxin reductase, 5-alpha-reductase, and DNA polymerases. In anaerobic bacteria, azelaic acid impedes glycolysis. Along with these actions, azelaic acid also improves acne vulgaris by normalizing the keratin process and decreasing microcomedo formation. Azelaic acid may be effective against both inflamed and noninflamed lesions. Specifically, azelaic acid reduces the thickness of the stratum corneum, shrinks keratohyalin granules by reducing the amount and distribution of filaggrin (a component of keratohyalin) in epidermal layers, and lowers the number of keratohyalin granules.

# Melting_Point:
106.5 °C

# Molecular_Weight_Avg:
188.2209

# Molecular_Weight_Mono:
188.104859

# Organisms_Affected:
Various aerobic and anaerobic microorganisms

# PDB_Experimental_ID:
1TUF

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/aze1043.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA164754850

# Pharmacology:
Azelaic acid is a saturated dicarboxylic acid found naturally in wheat, rye, and barley. It is a natural substance that is produced by <i>Malassezia furfur</i> (also known as <i>Pityrosporum ovale</i>), a yeast that lives on normal skin. It is effective against a number of skin conditions, such as mild to moderate acne, when applied topically in a cream formulation of 20%. It works in part by stopping the growth of skin bacteria that cause acne, and by keeping skin pores clear. Azelaic acid's antimicrobial action may be attributable to inhibition of microbial cellular protein synthesis.

# Predicted_LogP_Hydrophobicity:
1.37

# Predicted_LogS:
-1.9

# Predicted_Water_Solubility:
2.28e+00 g/l

# Primary_Accession_No:
DB00548

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
2266

# PubChem_Substance_ID:
46506284

# RxList_Link:
http://www.rxlist.com/cgi/generic3/azelex.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00812
EXPT00598

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC(=O)CCCCCCCC(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Anchoic acid
Azalaic Acid
Azelainic acid
Heptanedicarboxylic acid
Lepargylic acid
Nonanedioic acid
n-Nonanedioic acid

# Synthesis_Reference:
Not Available

# Toxicity:
Oral LD50 in rat: >5 g/kg

# Update_Date:
2013-02-08 16:19:26 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
4.55 (at 25 °C)

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
12386148	Hojo Y, Saito Y, Tanimoto T, Hoefen RJ, Baines CP, Yamamoto K, Haendeler J, Asmis R, Berk BC: Fluid shear stress attenuates hydrogen peroxide-induced c-Jun NH2-terminal kinase activation via a glutathione reductase-mediated mechanism. Circ Res. 2002 Oct 18;91(8):712-8.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2114832	Schallreuter KU, Wood JW: A possible mechanism of action for azelaic acid in the human epidermis. Arch Dermatol Res. 1990;282(3):168-71.
3652030	Schallreuter KU, Wood JM: Azelaic acid as a competitive inhibitor of thioredoxin reductase in human melanoma cells. Cancer Lett. 1987 Sep;36(3):297-305.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
BA000017

# Drug_Target_1_GenBank_ID_Protein:
14246533

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
trxB

# Drug_Target_1_Gene_Sequence:
>936 bp
ATGACTGAAATAGATTTTGATATAGCAATTATCGGTGCAGGTCCAGCTGGTATGACTGCT
GCAGTATACGCATCACGTGCTAATTTAAAAACAGTTATGATTGAAAGAGGTATTCCAGGC
GGTCAAATGGCTAATACAGAAGAAGTAGAGAACTTCCCTGGTTTCGAAATGATTACAGGT
CCAGATTTATCTACAAAAATGTTTGAACACGCTAAAAAGTTTGGTGCAGTTTATCAATAT
GGAGATATTAAATCTGTAGAAGATAAAGGCGAATATAAAGTGATTAACTTTGGTAATAAA
GAATTAACAGCGAAAGCGGTCATTATTGCTACAGGTGCAGAATACAAGAAAATTGGTGTT
CCGGGTGAACAAGAACTTGGTGGACGCGGTGTAAGTTATTGTGCAGTATGTGATGGTGCA
TTCTTTAAAAATAAACGCCTATTCGTTATCGGTGGTGGTGACTCAGCAGTAGAAGAGGGA
ACATTCTTAACTAAATTTGCTGACAAAGTAACAATCGTTCACCGTCGTGATGAGTTACGT
GCACAGCGTATTTTACAAGATAGAGCATTCAAAAATGATAAAATCGACTTTATTTGGAGT
CATACTTTGAAATCAATTAATGAAAAAGACGGCAAAGTGGGTTCTGTGACATTAACGTCT
ACAAAAGATGGTTCAGAAGAAACACACGAGGCTGATGGTGTATTCATCTATATTGGTATG
AAACCATTAACAGCGCCATTTAAAGACTTAGGTATTACGAATGATGTTGGTTATATTGTG
ACAAAAGATGATATGACAACATCAGTACCAGGTATTTTTGCAGCAGGAGATGTTCGTGAC
AAAGGTTTACGCCAAATTGTCACTGCTACTGGCGATGGTAGTATTGCAGCGCAAAGTGCA
GCGGAATATATTGAACATTTAAACGATCAAGCTTAA

# Drug_Target_1_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_1_General_References:
11418146	Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, Kobayashi I, Cui L, Oguchi A, Aoki K, Nagai Y, Lian J, Ito T, Kanamori M, Matsumaru H, Maruyama A, Murakami H, Hosoyama A, Mizutani-Ui Y, Takahashi NK, Sawano T, Inoue R, Kaito C, Sekimizu K, Hirakawa H, Kuhara S, Goto S, Yabuzaki J, Kanehisa M, Yamashita A, Oshima K, Furuya K, Yoshino C, Shiba T, Hattori M, Ogasawara N, Hayashi H, Hiramatsu K: Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet. 2001 Apr 21;357(9264):1225-40.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
526

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
33616

# Drug_Target_1_Name:
Thioredoxin reductase

# Drug_Target_1_Number_of_Residues:
311

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00070	Pyr_redox
PF07992	Pyr_redox_2

# Drug_Target_1_Protein_Sequence:
>Thioredoxin reductase
MTEIDFDIAIIGAGPAGMTAAVYASRANLKTVMIERGIPGGQMANTEEVENFPGFEMITG
PDLSTKMFEHAKKFGAVYQYGDIKSVEDKGEYKVINFGNKELTAKAVIIATGAEYKKIGV
PGEQELGGRGVSYCAVCDGAFFKNKRLFVIGGGDSAVEEGTFLTKFADKVTIVHRRDELR
AQRILQDRAFKNDKIDFIWSHTLKSINEKDGKVGSVTLTSTKDGSEETHEADGVFIYIGM
KPLTAPFKDLGITNDVGYIVTKDDMTTSVPGIFAAGDVRDKGLRQIVTATGDGSIAAQSA
AEYIEHLNDQA

# Drug_Target_1_Reaction:
thioredoxin + NADP+ = thioredoxin disulfide + NADPH + H+

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P66010

# Drug_Target_1_SwissProt_Name:
TRXB_STAAM

# Drug_Target_1_Synonyms:
EC 1.8.1.9
TRXR

# Drug_Target_1_Theoretical_pI:
5.00

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasm

# Drug_Target_2_Chromosome_Location:
7

# Drug_Target_2_Drug_References:
3207614	Stamatiadis D, Bulteau-Portois MC, Mowszowicz I: Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988 Nov;119(5):627-32.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Z28339

# Drug_Target_2_GenBank_ID_Protein:
431857

# Drug_Target_2_GeneCard_ID:
AKR1D1

# Drug_Target_2_Gene_Name:
AKR1D1

# Drug_Target_2_Gene_Sequence:
>981 bp
ATGGATCTCAGTGCTGCAAGTCACCGCATACCTCTAAGTGATGGAAACAGCATTCCCATC
ATCGGACTTGGTACCTACTCAGAACCTAAATCGACCCCTAAGGGAGCCTGTGCAACATCG
GTGAAGGTTGCTATTGACACAGGGTACCGACATATTGATGGGGCCTACATCTACCAAAAT
GAACACGAAGTTGGGGAGGCCATCAGGGAGAAGATAGCAGAAGGAAAGGTGCGGAGGGAA
GATATCTTCTACTGTGGAAAGCTATGGGCTACAAATCATGTCCCAGAGATGGTCCGCCCA
ACCCTGGAGAGGACACTCAGGGTCCTCCAGCTAGATTATGTGGATCTTTACATCATTGAA
GTACCCATGGCCTTTAAGCCAGGAGATGAAATATACCCTAGAGATGAGAATGGCAAATGG
TTATATCACAAGTCAAATCTGTGTGCCACTTGGGAGGCGATGGAAGCTTGCAAAGACGCT
GGCTTGGTGAAATCCCTGGGAGTGTCCAATTTTAACCGCAGGCAGCTGGAGCTCATCCTG
AACAAGCCAGGACTCAAACACAAGCCAGTCAGCAACCAGGTTGAGTGCCATCCGTATTTC
ACCCAGCCAAAACTCTTGAAATTTTGCCAACAACATGACATTGTCATTACTGCATATAGC
CCTTTGGGGACCAGTAGGAATCCAATCTGGGTGAATGTTTCTTCTCCACCTTTGTTAAAG
GATGCACTTCTAAACTCATTGGGGAAAAGGTACAATAAGACAGCAGCTCAAATTGTTTTG
CGTTTCAACATCCAGCGAGGGGTGGTTGTCATTCCTAAAAGCTTTAATCTTGAAAGGATC
AAAGAAAATTTTCAGATCTTTGACTTTTCTCTCACTGAAGAAGAAATGAAGGACATTGAA
GCCTTGAATAAAAATGTCCGCTTTGTAGAATTGCTCATGTGGCGCGATCATCCTGAATAC
CCATTTCATGATGAATACTGA

# Drug_Target_2_General_Function:
Involved in aldo-keto reductase activity

# Drug_Target_2_General_References:
11342103	Charbonneau A, The VL: Genomic organization of a human 5beta-reductase and its pseudogene and substrate selectivity of the expressed enzyme. Biochim Biophys Acta. 2001 Jan 26;1517(2):228-35.
12690205	Scherer SW, Cheung J, MacDonald JR, Osborne LR, Nakabayashi K, Herbrick JA, Carson AR, Parker-Katiraee L, Skaug J, Khaja R, Zhang J, Hudek AK, Li M, Haddad M, Duggan GE, Fernandez BA, Kanematsu E, Gentles S, Christopoulos CC, Choufani S, Kwasnicka D, Zheng XH, Lai Z, Nusskern D, Zhang Q, Gu Z, Lu F, Zeesman S, Nowaczyk MJ, Teshima I, Chitayat D, Shuman C, Weksberg R, Zackai EH, Grebe TA, Cox SR, Kirkpatrick SJ, Rahman N, Friedman JM, Heng HH, Pelicci PG, Lo-Coco F, Belloni E, Shaffer LG, Pober B, Morton CC, Gusella JF, Bruns GA, Korf BR, Quade BJ, Ligon AH, Ferguson H, Higgins AW, Leach NT, Herrick SR, Lemyre E, Farra CG, Kim HG, Summers AM, Gripp KW, Roberts W, Szatmari P, Winsor EJ, Grzeschik KH, Teebi A, Minassian BA, Kere J, Armengol L, Pujana MA, Estivill X, Wilson MD, Koop BF, Tosi S, Moore GE, Boright AP, Zlotorynski E, Kerem B, Kroisel PM, Petek E, Oscier DG, Mould SJ, Dohner H, Dohner K, Rommens JM, Vincent JB, Venter JC, Li PW, Mural RJ, Adams MD, Tsui LC: Human chromosome 7: DNA sequence and biology. Science. 2003 May 2;300(5620):767-72. Epub 2003 Apr 10.
12970144	Lemonde HA, Custard EJ, Bouquet J, Duran M, Overmars H, Scambler PJ, Clayton PT: Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid 5beta-reductase, in hepatitis and liver failure in infancy. Gut. 2003 Oct;52(10):1494-9.
14702039	Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.
15030995	Gonzales E, Cresteil D, Baussan C, Dabadie A, Gerhardt MF, Jacquemin E: SRD5B1 (AKR1D1) gene analysis in delta(4)-3-oxosteroid 5beta-reductase deficiency: evidence for primary genetic defect. J Hepatol. 2004 Apr;40(4):716-8.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
18407998	Di Costanzo L, Drury JE, Penning TM, Christianson DW: Crystal structure of human liver Delta4-3-ketosteroid 5beta-reductase (AKR1D1) and implications for substrate binding and catalysis. J Biol Chem. 2008 Jun 13;283(24):16830-9. Epub 2008 Apr 11.
7508385	Kondo KH, Kai MH, Setoguchi Y, Eggertsen G, Sjoblom P, Setoguchi T, Okuda KI, Bjorkhem I: Cloning and expression of cDNA of human delta 4-3-oxosteroid 5 beta-reductase and substrate specificity of the expressed enzyme. Eur J Biochem. 1994 Jan 15;219(1-2):357-63.

# Drug_Target_2_HGNC_ID:
GNC:388

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6105

# Drug_Target_2_Locus:
7q32-q33

# Drug_Target_2_Molecular_Weight:
37376.6

# Drug_Target_2_Name:
3-oxo-5-beta-steroid 4-dehydrogenase

# Drug_Target_2_Number_of_Residues:
326

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_2_Protein_Sequence:
>3-oxo-5-beta-steroid 4-dehydrogenase
MDLSAASHRIPLSDGNSIPIIGLGTYSEPKSTPKGACATSVKVAIDTGYRHIDGAYIYQN
EHEVGEAIREKIAEGKVRREDIFYCGKLWATNHVPEMVRPTLERTLRVLQLDYVDLYIIE
VPMAFKPGDEIYPRDENGKWLYHKSNLCATWEAMEACKDAGLVKSLGVSNFNRRQLELIL
NKPGLKHKPVSNQVECHPYFTQPKLLKFCQQHDIVITAYSPLGTSRNPIWVNVSSPPLLK
DALLNSLGKRYNKTAAQIVLRFNIQRGVVVIPKSFNLERIKENFQIFDFSLTEEEMKDIE
ALNKNVRFVELLMWRDHPEYPFHDEY

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Efficiently catalyzes the reduction of progesterone, androstenedione, 17-alpha-hydroxyprogesterone and testosterone to 5-beta-reduced metabolites. The bile acid intermediates 7- alpha,12-alpha-dihydroxy-4-cholesten-3-one and 7-alpha-hydroxy-4- cholesten-3-one can also act as substrates

# Drug_Target_2_SwissProt_ID:
P51857

# Drug_Target_2_SwissProt_Name:
AK1D1_HUMAN

# Drug_Target_2_Synonyms:
Aldo-keto reductase family 1 member D1
Delta(4)-3-ketosteroid 5-beta-reductase
Delta(4)-3-oxosteroid 5-beta-reductase

# Drug_Target_2_Theoretical_pI:
7.58

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Microsome
microsomal membrane
multi-pass membrane protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3207614	Stamatiadis D, Bulteau-Portois MC, Mowszowicz I: Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988 Nov;119(5):627-32.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
SRD5A2

# Drug_Target_3_GenBank_ID_Gene:
M74047

# Drug_Target_3_GenBank_ID_Protein:
338469

# Drug_Target_3_GeneCard_ID:
SRD5A2

# Drug_Target_3_Gene_Name:
SRD5A2

# Drug_Target_3_Gene_Sequence:
>765 bp
ATGCAGGTTCAGTGCCAGCAGAGCCCAGTGCTGGCAGGCAGCGCCACTTTGGTCGCCCTT
GGGGCACTGGCCTTGTACGTCGCGAAGCCCTCCGGCTACGGGAAGCACACGGAGAGCCTG
AAGCCGGCGGCTACCCGCCTGCCAGCCCGCGCCGCCTGGTTCCTGCAGGAGCTGCCTTCC
TTCGCGGTGCCCGCGGGGATCCTCGCCCGGCAGCCCCTCTCCCTCTTCGGGCCACCTGGG
ACGGTACTTCTGGGCCTCTTCTGCGTACATTACTTCCACAGGACATTTGTGTACTCACTG
CTCAATCGAGGGAGGCCTTATCCAGCTATACTCATTCTCAGAGGCACTGCCTTCTGCACT
GGAAATGGAGTCCTTCAAGGCTACTATCTGATTTACTGTGCTGAATACCCTGATGGGTGG
TACACAGACATACGGTTTAGCTTGGGTGTCTTCTTATTTATTTTGGGAATGGGAATAAAC
ATTCATAGTGACTATATATTGCGCCAGCTCAGGAAGCCTGGAGAAATCAGCTACAGGATT
CCACAAGGTGGCTTGTTTACGTATGTTTCTGGAGCCAATTTCCTCGGTGAGATCATTGAA
TGGATCGGCTATGCCCTGGCCACTTGGTCCCTCCCAGCACTTGCATTTGCATTTTTCTCA
CTTTGTTTCCTTGGGCTGCGAGCTTTTCACCACCATAGGTTCTACCTCAAGATGTTTGAG
GACTACCCCAAATCTCGGAAAGCCCTTATTCCATTCATCTTTTAA

# Drug_Target_3_General_Function:
Involved in sterol 5-alpha reductase activity

# Drug_Target_3_General_References:
10501358	Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE, Reichardt JK: Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet. 1999 Sep 18;354(9183):975-8.
10718838	Vilchis F, Mendez JP, Canto P, Lieberman E, Chavez B: Identification of missense mutations in the SRD5A2 gene from patients with steroid 5alpha-reductase 2 deficiency. Clin Endocrinol (Oxf). 2000 Mar;52(3):383-7.
10999800	Chavez B, Valdez E, Vilchis F: Uniparental disomy in steroid 5alpha-reductase 2 deficiency. J Clin Endocrinol Metab. 2000 Sep;85(9):3147-50.
11927504	Pearce CL, Makridakis NM, Ross RK, Pike MC, Kolonel LN, Henderson BE, Reichardt JK: Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study. Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):417-8.
1505484	Labrie F, Sugimoto Y, Luu-The V, Simard J, Lachance Y, Bachvarov D, Leblanc G, Durocher F, Paquet N: Structure of human type II 5 alpha-reductase gene. Endocrinology. 1992 Sep;131(3):1571-3.
1522235	Thigpen AE, Davis DL, Milatovich A, Mendonca BB, Imperato-McGinley J, Griffin JE, Francke U, Wilson JD, Russell DW: Molecular genetics of steroid 5 alpha-reductase 2 deficiency. J Clin Invest. 1992 Sep;90(3):799-809.
1944596	Andersson S, Berman DM, Jenkins EP, Russell DW: Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. Nature. 1991 Nov 14;354(6349):159-61.
7554313	Boudon C, Lobaccaro JM, Lumbroso S, Ogur G, Ocal G, Belon C, Sultan C: A new deletion of the 5 alpha-reductase type 2 gene in a Turkish family with 5 alpha-reductase deficiency. Clin Endocrinol (Oxf). 1995 Aug;43(2):183-8.
8626825	Cai LQ, Zhu YS, Katz MD, Herrera C, Baez J, DeFillo-Ricart M, Shackleton CH, Imperato-McGinley J: 5 alpha-reductase-2 gene mutations in the Dominican Republic. J Clin Endocrinol Metab. 1996 May;81(5):1730-5.
8768837	Hochberg Z, Chayen R, Reiss N, Falik Z, Makler A, Munichor M, Farkas A, Goldfarb H, Ohana N, Hiort O: Clinical, biochemical, and genetic findings in a large pedigree of male and female patients with 5 alpha-reductase 2 deficiency. J Clin Endocrinol Metab. 1996 Aug;81(8):2821-7.
9208814	Anwar R, Gilbey SG, New JP, Markham AF: Male pseudohermaphroditism resulting from a novel mutation in the human steroid 5 alpha-reductase type 2 gene (SRD5A2). Mol Pathol. 1997 Feb;50(1):51-2.
9745434	Nordenskjold A, Ivarsson SA: Molecular characterization of 5 alpha-reductase type 2 deficiency and fertility in a Swedish family. J Clin Endocrinol Metab. 1998 Sep;83(9):3236-8.
9843052	Nordenskjold A, Magnus O, Aagenaes O, Knudtzon J: Homozygous mutation (A228T) in the 5alpha-reductase type 2 gene in a boy with 5alpha-reductase deficiency: genotype-phenotype correlations. Am J Med Genet. 1998 Nov 16;80(3):269-72.

# Drug_Target_3_HGNC_ID:
HGNC:11285

# Drug_Target_3_HPRD_ID:
07390

# Drug_Target_3_ID:
642

# Drug_Target_3_Locus:
2p23

# Drug_Target_3_Molecular_Weight:
28394

# Drug_Target_3_Name:
3-oxo-5-alpha-steroid 4-dehydrogenase 2

# Drug_Target_3_Number_of_Residues:
254

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF02544	Steroid_dh

# Drug_Target_3_Protein_Sequence:
>3-oxo-5-alpha-steroid 4-dehydrogenase 2
MQVQCQQSPVLAGSATLVALGALALYVAKPSGYGKHTESLKPAATRLPARAAWFLQELPS
FAVPAGILARQPLSLFGPPGTVLLGLFCVHYFHRTFVYSLLNRGRPYPAILILRGTAFCT
GNGVLQGYYLIYCAEYPDGWYTDIRFSLGVFLFILGMGINIHSDYILRQLRKPGEISYRI
PQGGLFTYVSGANFLGEIIEWIGYALATWSLPALAFAFFSLCFLGLRAFHHHRFYLKMFE
DYPKSRKALIPFIF

# Drug_Target_3_Reaction:
a 3-oxo-5alpha-steroid + acceptor = a 3-oxo-Delta4-steroid + reduced acceptor

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Converts testosterone (T) into 5-alpha- dihydrotestosterone (DHT) and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology

# Drug_Target_3_SwissProt_ID:
P31213

# Drug_Target_3_SwissProt_Name:
S5A2_HUMAN

# Drug_Target_3_Synonyms:
5 alpha-SR2
EC 1.3.99.5
SR type 2
Steroid 5- alpha-reductase 2
Type II 5-alpha reductase

# Drug_Target_3_Theoretical_pI:
9.62

# Drug_Target_3_Transmembrane_Regions:
8-28
72-92
146-166
206-226

# Drug_Target_4_Cellular_Location:
Melanosome
melanosomal membrane
single- pass type I membrane protein

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
2114832	Schallreuter KU, Wood JW: A possible mechanism of action for azelaic acid in the human epidermis. Arch Dermatol Res. 1990;282(3):168-71.
2963038	Nazzaro-Porro M: Azelaic acid. J Am Acad Dermatol. 1987 Dec;17(6):1033-41.
4004885	Picardo M, Passi S, Sirianni MC, Fiorilli M, Russo GD, Cortesi E, Barile G, Breathnach AS, Nazzaro-Porro M: Activity of azelaic acid on cultures of lymphoma- and leukemia-derived cell lines, normal resting and stimulated lymphocytes and 3T3 fibroblasts. Biochem Pharmacol. 1985 May 15;34(10):1653-8.
448162	Nazzaro-Porro M, Passi S, Balus L, Breathnach A, Martin B, Morpurgo G: Effect of dicarboxylic acids on lentigo maligna. J Invest Dermatol. 1979 Jun;72(6):296-305.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
TYR

# Drug_Target_4_GenBank_ID_Gene:
M27160

# Drug_Target_4_GenBank_ID_Protein:
340037

# Drug_Target_4_GeneCard_ID:
TYR

# Drug_Target_4_Gene_Name:
TYR

# Drug_Target_4_Gene_Sequence:
>1590 bp
ATGCTCCTGGCTGTTTTGTACTGCCTGCTGTGGAGTTTCCAGACCTCCGCTGGCCATTTC
CCTAGAGCCTGTGTCTCCTCTAAGAACCTGATGGAGAAGGAATGCTGTCCACCGTGGAGC
GGGGACAGGAGTCCCTGTGGCCAGCTTTCAGGCAGAGGTTCCTGTCAGAATATCCTTCTG
TCCAATGCACCACTTGGGCCTCAATTTCCCTTCACAGGGGTGGATGACCGGGAGTCGTGG
CCTTCCGTCTTTTATAATAGGACCTGCCAGTGCTCTGGCAACTTCATGGGATTCAACTGT
GGAAACTGCAAGTTTGGCTTTTGGGGACCAAACTGCACAGAGAGACGACTCTTGGTGAGA
AGAAACATCTTCGATTTGAGTGCCCCAGAGAAGGACAAATTTTTTGCCTACCTCACTTTA
GCAAAGCATACCATCAGCTCAGACTATGTCATCCCCATAGGGACCTATGGCCAAATGAAA
AATGGATCAACACCCATGTTTAACGACATCAATATTTATGACCTCTTTGTCTGGATGCAT
TATTATGTGTCAATGGATGCACTGCTTGGGGGATCTGAAATCTGGAGAGACATTGATTTT
GCCCATGAAGCACCAGCTTTTCTGCCTTGGCATAGACTCTTCTTGTTGCGGTGGGAACAA
GAAATCCAGAAGCTGACAGGAGATGAAAACTTCACTATTCCATATTGGGACTGGCGGGAT
GCAGAAAAGTGTGACATTTGCACAGATGAGTACATGGGAGGTCAGCACCCCACAAATCCT
AACTTACTCAGCCCAGCATCATTCTTCTCCTCTTGGCAGATTGTCTGTAGCCGATTGGAG
GAGTACAACAGCCATCAGTCTTTATGCAATGGAACGCCCGAGGGACCTTTACGGCGTAAT
CCTGGAAACCATGACAAATCCAGAACCCCAAGGCTCCCCTCTTCAGCTGATGTAGAATTT
TGCCTGAGTTTGACCCAATATGAATCTGGTTCCATGGATAAAGCTGCCAATTTCAGCTTT
AGAAATACACTGGAAGGATTTGCTAGTCCACTTACTGGGATAGCGGATGCCTCTCAAAGC
AGCATGCACAATGCCTTGCACATCTATATGAATGGAACAATGTCCCAGGTACAGGGATCT
GCCAACGATCCTATCTTCCTTCTTCACCATGCATTTGTTGACAGTATTTTTGAGCAGTGG
CTCCGAAGGCACCGTCCTCTTCAAGAAGTTTATCCAGAAGCCAATGCACCCATTGGACAT
AACCGGGAATCCTACATGGTTCCTTTTATACCACTGTACAGAAATGGTGATTTCTTTATT
TCATCCAAAGATCTGGGCTATGACTATAGCTATCTACAAGATTCAGACCCAGACTCTTTT
CAAGACTACATTAAGTCCTATTTGGAACAAGCGAGTCGGATCTGGTCATGGCTCCTTGGG
GCGGCGATGGTAGGGGCCGTCCTCACTGCCCTGCTGGCAGGGCTTGTGAGCTTGCTGTGT
CGTCACAAGAGAAAGCAGCTTCCTGAAGAAAAGCAGCCACTCCTCATGGAGAAAGAGGAT
TACCACAGCTTGTATCAGAGCCATTTATAA

# Drug_Target_4_General_Function:
Involved in oxidoreductase activity

# Drug_Target_4_General_References:
10094567	Oetting WS, King RA: Molecular basis of albinism: mutations and polymorphisms of pigmentation genes associated with albinism. Hum Mutat. 1999;13(2):99-115.
10571953	Tsai CH, Tsai FJ, Wu JY, Lin SP, Chang JG, Yang CF, Lee CC: Insertion/deletion mutations of type I oculocutaneous albinism in chinese patients from Taiwan. Hum Mutat. 1999 Dec;14(6):542.
10987646	Passmore LA, Kaesmann-Kellner B, Weber BH: Novel and recurrent mutations in the tyrosinase gene and the P gene in the German albino population. Hum Genet. 1999 Sep;105(3):200-10.
11153699	Martinez-Arias R, Comas D, Andres A, Abello MT, Domingo-Roura X, Bertranpetit J: The tyrosinase gene in gorillas and the albinism of 'Snowflake'. Pigment Cell Res. 2000 Dec;13(6):467-70.
11214319	Murphy WJ, Eizirik E, Johnson WE, Zhang YP, Ryder OA, O'Brien SJ: Molecular phylogenetics and the origins of placental mammals. Nature. 2001 Feb 1;409(6820):614-8.
11295837	Camand O, Marchant D, Boutboul S, Pequignot M, Odent S, Dollfus H, Sutherland J, Levin A, Menasche M, Marsac C, Dufier JL, Heon E, Abitbol M: Mutation analysis of the tyrosinase gene in oculocutaneous albinism. Hum Mutat. 2001 Apr;17(4):352.
11858948	Nakamura E, Miyamura Y, Matsunaga J, Kano Y, Dakeishi-Hara M, Tanita M, Kono M, Tomita Y: A novel mutation of the tyrosinase gene causing oculocutaneous albinism type 1 (OCA1). J Dermatol Sci. 2002 Feb;28(2):102-5.
1487241	Oetting WS, King RA: Molecular analysis of type I-A (tyrosinase negative) oculocutaneous albinism. Hum Genet. 1992 Nov;90(3):258-62.
1642278	Tripathi RK, Strunk KM, Giebel LB, Weleber RG, Spritz RA: Tyrosinase gene mutations in type I (tyrosinase-deficient) oculocutaneous albinism define two clusters of missense substitutions. Am J Med Genet. 1992 Jul 15;43(5):865-71.
1711223	Chintamaneni CD, Halaban R, Kobayashi Y, Witkop CJ Jr, Kwon BS: A single base insertion in the putative transmembrane domain of the tyrosinase gene as a cause for tyrosinase-negative oculocutaneous albinism. Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5272-6.
1899321	Spritz RA, Strunk KM, Hsieh CL, Sekhon GS, Francke U: Homozygous tyrosinase gene mutation in an American black with tyrosinase-negative (type IA) oculocutaneous albinism. Am J Hum Genet. 1991 Feb;48(2):318-24.
1900309	Giebel LB, Tripathi RK, King RA, Spritz RA: A tyrosinase gene missense mutation in temperature-sensitive type I oculocutaneous albinism. A human homologue to the Siamese cat and the Himalayan mouse. J Clin Invest. 1991 Mar;87(3):1119-22.
1903356	Giebel LB, Strunk KM, Spritz RA: Organization and nucleotide sequences of the human tyrosinase gene and a truncated tyrosinase-related segment. Genomics. 1991 Mar;9(3):435-45.
1903591	Giebel LB, Tripathi RK, Strunk KM, Hanifin JM, Jackson CE, King RA, Spritz RA: Tyrosinase gene mutations associated with type IB ("yellow") oculocutaneous albinism. Am J Hum Genet. 1991 Jun;48(6):1159-67.
1943686	King RA, Mentink MM, Oetting WS: Non-random distribution of missense mutations within the human tyrosinase gene in type I (tyrosinase-related) oculocutaneous albinism. Mol Biol Med. 1991 Feb;8(1):19-29.
1970634	Giebel LB, Strunk KM, King RA, Hanifin JM, Spritz RA: A frequent tyrosinase gene mutation in classic, tyrosinase-negative (type IA) oculocutaneous albinism. Proc Natl Acad Sci U S A. 1990 May;87(9):3255-8.
2342539	Spritz RA, Strunk KM, Giebel LB, King RA: Detection of mutations in the tyrosinase gene in a patient with type IA oculocutaneous albinism. N Engl J Med. 1990 Jun 14;322(24):1724-8.
2480811	Kikuchi H, Miura H, Yamamoto H, Takeuchi T, Dei T, Watanabe M: Characteristic sequences in the upstream region of the human tyrosinase gene. Biochim Biophys Acta. 1989 Dec 22;1009(3):283-6.
2499655	Bouchard B, Fuller BB, Vijayasaradhi S, Houghton AN: Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. J Exp Med. 1989 Jun 1;169(6):2029-42.
2504160	Takeda A, Tomita Y, Okinaga S, Tagami H, Shibahara S: Functional analysis of the cDNA encoding human tyrosinase precursor. Biochem Biophys Res Commun. 1989 Aug 15;162(3):984-90.
2823263	Kwon BS, Haq AK, Pomerantz SH, Halaban R: Isolation and sequence of a cDNA clone for human tyrosinase that maps at the mouse c-albino locus. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7473-7.
7902671	Tripathi RK, Bundey S, Musarella MA, Droetto S, Strunk KM, Holmes SA, Spritz RA: Mutations of the tyrosinase gene in Indo-Pakistani patients with type I (tyrosinase-deficient) oculocutaneous albinism (OCA). Am J Hum Genet. 1993 Dec;53(6):1173-9.
7955413	Breimer LH, Winder AF, Jay B, Jay M: Initiation codon mutation of the tyrosinase gene as a cause of human albinism. Clin Chim Acta. 1994 Jun;227(1-2):17-22.
8128955	Gershoni-Baruch R, Rosenmann A, Droetto S, Holmes S, Tripathi RK, Spritz RA: Mutations of the tyrosinase gene in patients with oculocutaneous albinism from various ethnic groups in Israel. Am J Hum Genet. 1994 Apr;54(4):586-94.
8340755	Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993 Aug 1;178(2):489-95.
8477259	Oetting WS, King RA: Molecular basis of type I (tyrosinase-related) oculocutaneous albinism: mutations and polymorphisms of the human tyrosinase gene. Hum Mutat. 1993;2(1):1-6.
8644824	Summers CG, Oetting WS, King RA: Diagnosis of oculocutaneous albinism with molecular analysis. Am J Ophthalmol. 1996 Jun;121(6):724-6.
9158138	Morell R, Spritz RA, Ho L, Pierpont J, Guo W, Friedman TB, Asher JH Jr: Apparent digenic inheritance of Waardenburg syndrome type 2 (WS2) and autosomal recessive ocular albinism (AROA). Hum Mol Genet. 1997 May;6(5):659-64.
9259202	Spritz RA, Oh J, Fukai K, Holmes SA, Ho L, Chitayat D, France TD, Musarella MA, Orlow SJ, Schnur RE, Weleber RG, Levin AV: Novel mutations of the tyrosinase (TYR) gene in type I oculocutaneous albinism (OCA1). Hum Mutat. 1997;10(2):171-4.

# Drug_Target_4_HGNC_ID:
HGNC:12442

# Drug_Target_4_HPRD_ID:
06086

# Drug_Target_4_ID:
279

# Drug_Target_4_Locus:
11q14-q21

# Drug_Target_4_Molecular_Weight:
60394

# Drug_Target_4_Name:
Tyrosinase

# Drug_Target_4_Number_of_Residues:
529

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00264	Tyrosinase

# Drug_Target_4_Protein_Sequence:
>Tyrosinase precursor
MLLAVLYCLLWSFQTSAGHFPRACVSSKNLMEKECCPPWSGDRSPCGQLSGRGSCQNILL
SNAPLGPQFPFTGVDDRESWPSVFYNRTCQCSGNFMGFNCGNCKFGFWGPNCTERRLLVR
RNIFDLSAPEKDKFFAYLTLAKHTISSDYVIPIGTYGQMKNGSTPMFNDINIYDLFVWMH
YYVSMDALLGGSEIWRDIDFAHEAPAFLPWHRLFLLRWEQEIQKLTGDENFTIPYWDWRD
AEKCDICTDEYMGGQHPTNPNLLSPASFFSSWQIVCSRLEEYNSHQSLCNGTPEGPLRRN
PGNHDKSRTPRLPSSADVEFCLSLTQYESGSMDKAANFSFRNTLEGFASPLTGIADASQS
SMHNALHIYMNGTMSQVQGSANDPIFLLHHAFVDSIFEQWLRRHRPLQEVYPEANAPIGH
NRESYMVPFIPLYRNGDFFISSKDLGYDYSYLQDSDPDSFQDYIKSYLEQASRIWSWLLG
AAMVGAVLTALLAGLVSLLCRHKRKQLPEEKQPLLMEKEDYHSLYQSHL

# Drug_Target_4_Reaction:
L-tyrosine + L-dopa + O2 = L-dopa + dopaquinone + H2O

# Drug_Target_4_Signals:
1-18

# Drug_Target_4_Specific_Function:
This is a copper-containing oxidase that functions in the formation of pigments such as melanins and other polyphenolic compounds. Catalyzes the rate-limiting conversions of tyrosine to DOPA, DOPA to DOPA-quinone and possibly 5,6-dihydroxyindole to indole-5,6 quinone

# Drug_Target_4_SwissProt_ID:
P14679

# Drug_Target_4_SwissProt_Name:
TYRO_HUMAN

# Drug_Target_4_Synonyms:
EC 1.14.18.1
LB24-AB
Monophenol monooxygenase
SK29-AB
Tumor rejection antigen AB
Tyrosinase precursor

# Drug_Target_4_Theoretical_pI:
6.05

# Drug_Target_4_Transmembrane_Regions:
477-497

# Drug_Target_5_Cellular_Location:
Cytoplasmic

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2475996	Galhaup I: Azelaic acid: mode of action at cellular and subcellular levels. Acta Derm Venereol Suppl (Stockh). 1989;143:75-82.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
V00317

# Drug_Target_5_GenBank_ID_Protein:
42461

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
polA

# Drug_Target_5_Gene_Sequence:
>2787 bp
ATGGTTCAGATCCCCCAAAATCCACTTATCCTTGTAGATGGTTCATCTTATCTTTATCGC
GCATATCACGCGTTTCCCCCGCTGACTAACAGCGCAGGCGAGCCGACCGGTGCGATGTAT
GGTGTCCTCAACATGCTGCGCAGTCTGATCATGCAATATAAACCGACGCATGCAGCGGTG
GTCTTTGACGCCAAGGGAAAAACCTTTCGTGATGAACTGTTTGAACATTACAAATCACAT
CGCCCGCCAATGCCGGACGATCTGCGTGCACAAATCGAACCCTTGCACGCGATGGTTAAA
GCGATGGGACTGCCGCTGCTGGCGGTTTCTGGCGTAGAAGCGGACGACGTTATCGGTACT
CTGGCGCGCGAAGCCGAAAAAGCCGGGCGTCCGGTGCTGATCAGCACTGGCGATAAAGAT
ATGGCGCAGCTGGTGACGCCAAATATTACGCTTATCAATACCATGACGAATACCATCCTC
GGACCGGAAGAGGTGGTGAATAAGTACGGCGTGCCGCCAGAACTGATCATCGATTTCCTG
GCGCTGATGGGTGACTCCTCTGATAACATTCCTGGCGTACCGGGCGTCGGTGAAAAAACC
GCGCAGGCATTGCTGCAAGGTCTTGGCGGACTGGATACGCTGTATGCCGAGCCAGAAAAA
ATTGCTGGGTTGAGCTTCCGTGGCGCGAAAACAATGGCAGCGAAGCTCGAGCAAAACAAA
GAAGTTGCTTATCTCTCATACCAGCTGGCGACGATTAAAACCGACGTTGAACTGGAGCTG
ACCTGTGAACAACTGGAAGTGCAGCAACCGGCAGCGGAAGAGTTGTTGGGGCTGTTCAAA
AAGTATGAGTTCAAACGCTGGACTGCTGATGTCGAAGCGGGCAAATGGTTACAGGCCAAA
GGGGCAAAACCAGCCGCGAAGCCACAGGAAACCAGTGTTGCAGACGAAGCACCAGAAGTG
ACGGCAACGGTGATTTCTTATGACAACTACGTCACCATCCTTGATGAAGAAACACTGAAA
GCGTGGATTGCGAAGCTGGAAAAAGCGCCGGTATTTGCATTTGATACCGAAACCGACAGC
CTTGATAACATCTCTGCTAACCTGGTCGGGCTTTCTTTTGCTATCGAGCCAGGCGTAGCG
GCATATATTCCGGTTGCTCATGATTATCTTGATGCGCCCGATCAAATCTCTCGCGAGCGT
GCACTCGAGTTGCTAAAACCGCTGCTGGAAGATGAAAAGGCGCTGAAGGTCGGGCAAAAC
CTGAAATACGATCGCGGTATTCTGGCGAACTACGGCATTGAACTGCGTGGGATTGCGTTT
GATACCATGCTGGAGTCCTACATTCTCAATAGCGTTGCCGGGCGTCACGATATGGACAGC
CTCGCGGAACGTTGGTTGAAGCACAAAACCATCACTTTTGAAGAGATTGCTGGTAAAGGC
AAAAATCAACTGACCTTTAACCAGATTGCCCTCGAAGAAGCCGGACGTTACGCCGCCGAA
GATGCAGATGTCACCTTGCAGTTGCATCTGAAAATGTGGCCGGATCTGCAAAAACACAAA
GGGCCGTTGAACGTCTTCGAGAATATCGAAATGCCGCTGGTGCCGGTGCTTTCACGCATT
GAACGTAACGGTGTGAAGATCGATCCGAAAGTGCTGCACAATCATTCTGAAGAGCTCACC
CTTCGTCTGGCTGAGCTGGAAAAGAAAGCGCATGAAATTGCAGGTGAGGAATTTAACCTT
TCTTCCACCAAGCAGTTACAAACCATTCTCTTTGAAAAACAGGGCATTAAACCGCTGAAG
AAAACGCCGGGTGGCGCGCCGTCAACGTCGGAAGAGGTACTGGAAGAACTGGCGCTGGAC
TATCCGTTGCCAAAAGTGATTCTGGAGTATCGTGGTCTGGCGAAGCTGAAATCGACCTAC
ACCGACAAGCTGCCGCTGATGATCAACCCGAAAACCGGGCGTGTGCATACCTCTTATCAC
CAGGCAGTAACTGCAACGGGACGTTTATCGTCAACCGATCCTAACCTGCAAAACATTCCG
GTGCGTAACGAAGAAGGTCGTCGTATCCGCCAGGCGTTTATTGCGCCAGAGGATTATGTG
ATTGTCTCAGCGGACTACTCGCAGATTGAACTGCGCATTATGGCGCATCTTTCGCGTGAC
AAAGGCTTGCTGACCGCATTCGCGGAAGGAAAAGATATCCACCGGGCAACGGCGGCAGAA
GTGTTTGGTTTGCCACTGGAAACCGTCACCAGCGAGCAACGCCGTAGCGCGAAAGCGATC
AACTTTGGTCTGATTTATGGCATGAGTGCTTTCGGTCTGGCGCGGCAATTGAACATTCCA
CGTAAAGAAGCGCAGAAGTACATGGACCTTTACTTCGAACGCTACCCTGGCGTGCTGGAG
TATATGGAACGCACCCGTGCTCAGGCGAAAGAGCAGGGCTACGTTGAAACGCTGGACGGA
CGCCGTCTGTATCTGCCGGATATCAAATCCAGCAATGGTGCTCGTCGTGCAGCGGCTGAA
CGTGCAGCCATTAACGCGCCAATGCAGGGAACCGCCGCCGACATTATCAAACGGGCGATG
ATTGCCGTTGATGCGTGGTTACAGGCTGAGCAACCGCGTGTACGTATGATCATGCAGGTA
CACGATGAACTGGTATTTGAAGTTCATAAAGATGATGTTGATGCCGTCGCGAAGCAGATT
CATCAACTGATGGAAAACTGTACCCGTCTGGATGTGCCGTTGCTGGTGGAAGTGGGGAGT
GGCGAAAACTGGGATCAGGCGCACTAA

# Drug_Target_5_General_Function:
Replication, recombination and repair

# Drug_Target_5_General_References:
10588690	Teplova M, Wallace ST, Tereshko V, Minasov G, Symons AM, Cook PD, Manoharan M, Egli M: Structural origins of the exonuclease resistance of a zwitterionic RNA. Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14240-5.
1989886	Beese LS, Steitz TA: Structural basis for the 3'-5' exonuclease activity of Escherichia coli DNA polymerase I: a two metal ion mechanism. EMBO J. 1991 Jan;10(1):25-33.
3883192	Ollis DL, Brick P, Hamlin R, Xuong NG, Steitz TA: Structure of large fragment of Escherichia coli DNA polymerase I complexed with dTMP. Nature. 1985 Feb 28-Mar 6;313(6005):762-6.
6183253	Joyce CM, Grindley ND: Identification of two genes immediately downstream from the polA gene of Escherichia coli. J Bacteriol. 1982 Dec;152(3):1211-9.
6276402	Joyce CM, Kelley WS, Grindley ND: Nucleotide sequence of the Escherichia coli polA gene and primary structure of DNA polymerase I. J Biol Chem. 1982 Feb 25;257(4):1958-64.
6302278	Kelley WS, Joyce CM: Genetic characterization of early amber mutations in the Escherichia coli polA gene and purification of the amber peptides. J Mol Biol. 1983 Mar 15;164(4):529-60.
7035456	Brown WE, Stump KH, Kelley WS: Escherichia coli DNA polymerase I. Sequence characterization and secondary structure prediction. J Biol Chem. 1982 Feb 25;257(4):1965-72.
8260491	Beese LS, Friedman JM, Steitz TA: Crystal structures of the Klenow fragment of DNA polymerase I complexed with deoxynucleoside triphosphate and pyrophosphate. Biochemistry. 1993 Dec 28;32(51):14095-101.
8346018	Plunkett G 3rd, Burland V, Daniels DL, Blattner FR: Analysis of the Escherichia coli genome. III. DNA sequence of the region from 87.2 to 89.2 minutes. Nucleic Acids Res. 1993 Jul 25;21(15):3391-8.
8442659	Mullen GP, Vaughn JB Jr, Mildvan AS: Sequential proton NMR resonance assignments, circular dichroism, and structural properties of a 50-residue substrate-binding peptide from DNA polymerase I. Arch Biochem Biophys. 1993 Feb 15;301(1):174-83.
8469987	Beese LS, Derbyshire V, Steitz TA: Structure of DNA polymerase I Klenow fragment bound to duplex DNA. Science. 1993 Apr 16;260(5106):352-5.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9514742	Brautigam CA, Steitz TA: Structural principles for the inhibition of the 3'-5' exonuclease activity of Escherichia coli DNA polymerase I by phosphorothioates. J Mol Biol. 1998 Mar 27;277(2):363-77.
9888810	Brautigam CA, Sun S, Piccirilli JA, Steitz TA: Structures of normal single-stranded DNA and deoxyribo-3'-S-phosphorothiolates bound to the 3'-5' exonucleolytic active site of DNA polymerase I from Escherichia coli. Biochemistry. 1999 Jan 12;38(2):696-704.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
553

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
103119

# Drug_Target_5_Name:
DNA polymerase I

# Drug_Target_5_Number_of_Residues:
928

# Drug_Target_5_PDB_ID:
1KFD

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00476	DNA_pol_A
PF01367	5_3_exonuc
PF01612	3_5_exonuc
PF02739	5_3_exonuc_N

# Drug_Target_5_Protein_Sequence:
>DNA polymerase I
MVQIPQNPLILVDGSSYLYRAYHAFPPLTNSAGEPTGAMYGVLNMLRSLIMQYKPTHAAV
VFDAKGKTFRDELFEHYKSHRPPMPDDLRAQIEPLHAMVKAMGLPLLAVSGVEADDVIGT
LAREAEKAGRPVLISTGDKDMAQLVTPNITLINTMTNTILGPEEVVNKYGVPPELIIDFL
ALMGDSSDNIPGVPGVGEKTAQALLQGLGGLDTLYAEPEKIAGLSFRGAKTMAAKLEQNK
EVAYLSYQLATIKTDVELELTCEQLEVQQPAAEELLGLFKKYEFKRWTADVEAGKWLQAK
GAKPAAKPQETSVADEAPEVTATVISYDNYVTILDEETLKAWIAKLEKAPVFAFDTETDS
LDNISANLVGLSFAIEPGVAAYIPVAHDYLDAPDQISRERALELLKPLLEDEKALKVGQN
LKYDRGILANYGIELRGIAFDTMLESYILNSVAGRHDMDSLAERWLKHKTITFEEIAGKG
KNQLTFNQIALEEAGRYAAEDADVTLQLHLKMWPDLQKHKGPLNVFENIEMPLVPVLSRI
ERNGVKIDPKVLHNHSEELTLRLAELEKKAHEIAGEEFNLSSTKQLQTILFEKQGIKPLK
KTPGGAPSTSEEVLEELALDYPLPKVILEYRGLAKLKSTYTDKLPLMINPKTGRVHTSYH
QAVTATGRLSSTDPNLQNIPVRNEEGRRIRQAFIAPEDYVIVSADYSQIELRIMAHLSRD
KGLLTAFAEGKDIHRATAAEVFGLPLETVTSEQRRSAKAINFGLIYGMSAFGLARQLNIP
RKEAQKYMDLYFERYPGVLEYMERTRAQAKEQGYVETLDGRRLYLPDIKSSNGARRAAAE
RAAINAPMQGTAADIIKRAMIAVDAWLQAEQPRVRMIMQVHDELVFEVHKDDVDAVAKQI
HQLMENCTRLDVPLLVEVGSGENWDQAH

# Drug_Target_5_Reaction:
deoxynucleoside triphosphate + DNAn = diphosphate + DNAn+1

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
In addition to polymerase activity, this DNA polymerase exhibits 3' to 5' and 5' to 3' exonuclease activity. It is able to utilize nicked circular duplex DNA as a template and can unwind the parental DNA strand from its template

# Drug_Target_5_SwissProt_ID:
P00582

# Drug_Target_5_SwissProt_Name:
DPO1_ECOLI

# Drug_Target_5_Synonyms:
EC 2.7.7.7
POL I

# Drug_Target_5_Theoretical_pI:
5.27

# Drug_Target_5_Transmembrane_Regions:
None

#END_DRUGCARD DB00548
